Finding. A new nitric-oxide donor kills triple-negative breast-cancer cells by using the ER-mitochondria contact as a ferroptosis bench. Long, Liu and colleagues build 3A72, a furan-coumarin NO releaser. It stops TNBC cells and xenografts, they say as well as paclitaxel and with less systemic harm. NO first overloads cytoplasmic calcium. The compound binds IP3R and ACSL4. IP3R binding overloads mitochondrial calcium and throws ROS. ACSL4 remodels phospholipids. Transcriptomes and structural predictions put that partnership at mitochondria-associated membranes, where ROS and lipid work make malondialdehyde and an irreversible ferroptosis.
Why this paper matters
Most ferroptosis drugs start at GPX4 or iron. This one starts at a contact site and a gasotransmitter. If the MAM geometry is real, you can think about IP3R-ACSL4 as a two-handed handle rather than two unrelated hits. The paclitaxel comparison is the translational bait; the MAM sentence is the mitochondrial one.
What they actually measured
Cells, xenografts, NO, calcium, ROS, binding claims, RNA-seq, structural prediction, MDA. The MAM convergence is predicted as well as inferred.
How to read the score
Mid 80s. MAM-centered ferroptosis with an in vivo arm. Confidence is medium because prediction is doing some of the spatial work.
Caveats
Predicted pairing. Check ferroptosis inhibitors and the paclitaxel figure. Do not dose patients with 3A72 from this brief.
What to do with it
If you drug MAMs, add IP3R plus ACSL4 as a pair. If you screen NO donors in TNBC, read mitochondrial calcium and MDA, not only cGMP. Pair it with this week's celecoxib-NDGA redox death: two CRC/breast redox papers that refuse simple ferroptosis labels or, here, embrace one with extra geometry.